6533b85afe1ef96bd12b964b
RESEARCH PRODUCT
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Angelyn BethelMatthew C. RiddleRafael DiazPatricio Lopez-jaramilloJonathan E. ShawFernando T LanasPurnima Rao-melaciniTali Cukierman-yaffeTali Cukierman-yaffeJeffrey L. ProbstfieldLuis-emilio Garcia-perezWayne H-h SheuValdis PiragsJan BasileEdward FranekDenis XavierNana PogosovaHelen M. ColhounHertzel C. GersteinStephanie HallCharles AtissoTheodora Temelkova-kurktschievMark LakshmananPeter J RaubenheimerWilliam C. CushmanLawrence A. LeiterMatyas KeltaiLars Rydénsubject
AdultMalemedicine.medical_specialtyRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHumansHypoglycemic AgentsCognitive DysfunctionRisk factorAgedbusiness.industryHazard ratioMontreal Cognitive AssessmentMiddle Agedmedicine.diseaseImmunoglobulin Fc FragmentsTreatment OutcomeDiabetes Mellitus Type 2Digit symbol substitution testFemaleDulaglutideNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugdescription
Digital
year | journal | country | edition | language |
---|---|---|---|---|
2020-07-01 |